Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacokinetics of levosimendan in severe patients undergoing continuous renal replacement therapy
ChiCTR2100053060Phase 4Recruiting
- Sponsor
- The First Affiliated Hospital of Sun Yat-sen University
- Start
- Dec 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of levosimendan in heart failure (HF) (2 arms), sponsored by The First Affiliated Hospital of Sun Yat-sen University. Primary endpoints: Pharmacokinetic indices of levosimendan, Pharmacokinetic indices of OR-1855 and OR-1896 and 1 more. Started Dec 2021; status: recruiting.
02
Drugs
levosimendan
03
Conditions
heart failure (HF)
Beyond the preview
Go deeper on ChiCTR2100053060.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100053060.